Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lyumjev with 50% basal rate reduction · 1 trial · 1 indication
Changes in PG from the start (0 minute) to end of exercise (60 minutes) were analyzed using a mixed-effect model. The model included treatment (Lyumjev with 50% basal reduction, Lyumjev with 100% basal reduction, Humalog with 50% basal reduction, and Humalog with 100% basal reduction), sequence, period, timepoint, treatment-by-timepoint interaction as fixed effects, and participant-within-sequence as a random effect.
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence 1: ADBC | EXPERIMENTAL | Period 1: Lyumjev with 50% basal rate reduction (Treatment A) Period 2: Humalog with 100% basal rate reduction (Treatment D) Period 3: Lyumjev with 100% basal rate reduction (Treatment B) Period 4: Humalog with 50% basal rate reduction (Treatment C) Participants received their assigned treatments in each of the above treatment period on Day 1 subcutaneously. |
| Treatment Sequence 2: BACD | EXPERIMENTAL | Period 1: Lyumjev with 100% basal rate reduction (Treatment B) Period 2: Lyumjev with 50% basal rate reduction (Treatment A) Period 3: Humalog with 50% basal rate reduction (Treatment C) Period 4: Humalog with 100% basal rate reduction (Treatment D) Participants received their assigned treatments in each of the above treatment period on Day 1 subcutaneously. |
| Treatment Sequence 3: CBDA | EXPERIMENTAL | Period 1: Humalog with 50% basal rate reduction (Treatment C) Period 2: Lyumjev with 100% basal rate reduction (Treatment B) Period 3: Humalog with 100% basal rate reduction (Treatment D) Period 4: Lyumjev with 50% basal rate reduction (Treatment A) Participants received their assigned treatments in each of the above treatment period on Day 1 subcutaneously. |
| Treatment Sequence 4: DCAB | EXPERIMENTAL | Period 1: Humalog with 100% basal rate reduction (Treatment D) Period 2: Humalog with 50% basal rate reduction (Treatment C) Period 3: Lyumjev with 50% basal rate reduction (Treatment A) Period 4: Lyumjev with 100% basal rate reduction (Treatment B) Participants received their assigned treatments in each of the above treatment period on Day 1 subcutaneously. |
| Name | Type | Description |
|---|---|---|
| Lyumjev with 50% basal rate reduction | DRUG | Administered SC. |
| Humalog with 50% basal rate reduction | DRUG | Administered SC. |
| Humalog with 100% basal rate reduction | DRUG | Administered SC. |
| Lyumjev with 100% basal rate reduction | DRUG | Administered SC. |
Inclusion Criteria: * Male or female participants with type 1 diabetes * Body mass index (BMI) between 18.5 and 29.0 kilograms per square meter (kg/m²), inclusive * Hemoglobin A1c (HbA1c) less than or equal to 8.5 percent (%) * Using CSII and stable insulin regimen for at least 6 months prior to in...
Lyumjev with 50% basal rate reduction is used for the treatment of Type 1 Diabetes Mellitus. It is an investigational small molecule being developed by Eli Lilly and Company. The drug is intended to manage blood glucose levels in patients with this condition.
Lyumjev with 50% basal rate reduction targets insulin receptors. It is a form of insulin lispro, a rapid-acting insulin analog, that works by replacing the insulin normally produced by the body to help regulate blood sugar levels in patients with Type 1 Diabetes Mellitus.
Lyumjev with 50% basal rate reduction is developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with Type 1 Diabetes Mellitus.
Lyumjev with 50% basal rate reduction is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied in a clinical trial to assess its effects in participants with Type 1 Diabetes Mellitus.
Lyumjev with 50% basal rate reduction is associated with one completed clinical trial, NCT05262387, titled 'A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes'. This Phase 1 trial enrolled 25 participants in Canada and was a randomized, double-blind, controlled study.
Yes, Lyumjev with 50% basal rate reduction is the same as LY900014. The clinical trial NCT05262387 refers to the drug as LY900014 (Lyumjev). This naming is used in the study to identify the investigational product being evaluated in participants with Type 1 Diabetes Mellitus.